Researchers set out to determine whether microglial activation, which can trigger neuroinflammation, is associated with neuropsychiatric symptoms that often accompany Alzheimer-associated dementias,...
Following two 12-week studies, the FDA has approved the first ever medication for treating agitation in patients with dementia due to Alzheimer disease.
Findings from 2 trials that compared various doses of the atypical antipsychotic brexpiprazole with placebo have indicated that the drug may have additional benefits for patients with agitation due to...
Researchers recently compared the effects of treatment with an atypical antipsychotic vs placebo for various periods of time among patients with Alzheimer disease psychosis.
A study investigated the neural mechanisms behind aggressive behaviors in patients with Alzheimer disease and amnestic mild cognitive impairment, revealing distinct associations between brain activity and...
A study on mild cognitive impairment found that depression and agitation are linked to regional brain atrophy and faster cognitive decline, suggesting these symptoms may indicate a higher risk for...
A cluster-randomized controlled trial examined the impact of personalized music on reducing agitation in nursing home residents with dementia, revealing significant reductions in verbally agitated behaviors...
